Literature DB >> 11334865

Activation of 5-HT(1B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study.

Q S Yan1, S E Yan.   

Abstract

This study was designed to investigate the role of 5-hydroxytryptamine (5-HT)(1B) receptors located in the ventral tegmental area and nucleus accumbens in the modulation of accumbal dopaminergic transmission. The selective 5-HT(1B) receptor agonist CP 93129 [3-(1,2,5,6-tetrahydro-4-pyridyl)pyrrolo[3,2-b]pyrid-5-one] was administered into the ventral tegmental area or nucleus accumbens of freely moving Sprague-Dawley rats via retrograde microdialysis. The effects of intra-accumbal and intra-tegmental CP 93129 on extracellular dopamine levels in the nucleus accumbens were measured using one- and dual-probe microdialysis, respectively. For dual-probe microdialysis, one probe was in the ventral tegmental area for drug administration and the other in the ipsilateral nucleus accumbens for dopamine measurement. The results show that infusion of CP 93129 (2, 5 and 10 microM) into the nucleus accumbens increased local dopamine levels in a concentration-related manner. Infusion of CP 93129 (10 and 20 microM) into the ventral tegmental area also increased dopamine levels in the ipsilateral nucleus accumbens. The increased dopamine release in the nucleus accumbens produced by intra-accumbal or intra-tegmental CP 93129 was antagonized by co-infusion of cyanopindolol (5 microM), a 5-HT(1B/1A) receptor antagonist, but not by WAY-100635 [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-2-pyridinyl-cyclohexanecarboxamide] (5 microM), a highly selective 5-HT(1A) receptor antagonist. In addition, augmentations of dopamine release in the nucleus accumbens induced by intra-accumbal CP 93129 were sensitive to Na(+) channel blockade with tetrodotoxin. These results are not in opposition to the concept that 5-HT(1B) receptors within the ventral tegmental area and nucleus accumbens are all involved in the modulation of dopamine release in the terminal area of the mesolimbic dopamine system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334865     DOI: 10.1016/s0014-2999(01)00913-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

1.  Serotonin 1B receptor imaging in pathological gambling.

Authors:  Marc N Potenza; Espen Walderhaug; Shannan Henry; Jean-Dominique Gallezot; Beata Planeta-Wilson; Jim Ropchan; Alexander Neumeister
Journal:  World J Biol Psychiatry       Date:  2011-09-22       Impact factor: 4.132

Review 2.  Opponency revisited: competition and cooperation between dopamine and serotonin.

Authors:  Y-Lan Boureau; Peter Dayan
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

3.  Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder.

Authors:  James W Murrough; Shannan Henry; Jian Hu; Jean-Dominique Gallezot; Beata Planeta-Wilson; John F Neumaier; Alexander Neumeister
Journal:  Psychopharmacology (Berl)       Date:  2010-05-18       Impact factor: 4.530

Review 4.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

Authors:  K D Alex; E A Pehek
Journal:  Pharmacol Ther       Date:  2006-10-17       Impact factor: 12.310

Review 5.  Neuroinflammation as a risk factor for attention deficit hyperactivity disorder.

Authors:  Geoffrey A Dunn; Joel T Nigg; Elinor L Sullivan
Journal:  Pharmacol Biochem Behav       Date:  2019-05-16       Impact factor: 3.533

Review 6.  Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity.

Authors:  Robert F Leeman; Marc N Potenza
Journal:  Psychopharmacology (Berl)       Date:  2011-11-05       Impact factor: 4.530

7.  Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system.

Authors:  Franck Chenu; Denis J P David; Isabelle Leroux-Nicollet; Erwan Le Maître; Alain M Gardier; Michel Bourin
Journal:  J Psychiatry Neurosci       Date:  2008-11       Impact factor: 6.186

8.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

9.  A history of caloric restriction induces neurochemical and behavioral changes in rats consistent with models of depression.

Authors:  P C Chandler-Laney; E Castaneda; C E Pritchett; M L Smith; M Giddings; A I Artiga; M M Boggiano
Journal:  Pharmacol Biochem Behav       Date:  2007-04-11       Impact factor: 3.533

10.  Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats.

Authors:  Susan Schenk; David Gittings; Malcolm Johnstone; Evangeline Daniela
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.